Vivesto AB (FRA:OMA)

Market Cap	7.00M -35.6%
Revenue (ttm)	n/a
Net Income	-2.85M
EPS	-0.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Open	0.5990
Previous Close	0.5630
Day's Range	0.5990 - 0.5990
52-Week Range	0.1400 - 1.9100
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OMA

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error